Neurological disorders and therapeutics targeted to surmount the blood–brain barrier

References

• RiggsJEAge specific rates of neurological diseaseHofPRMobbsCVFunctional Neurobiology of AgingSan DiegoCA Press: Academic Press2001
   Google Scholar
• CalvoPGouritinBVillarroyaHQuantification and localisation of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during allergic encephalomyelitis in the ratEur J Neurosci20021581317132611994126
   PubMed Web of Science ®Google Scholar
• JainKKThe role of nanobiotechnology in drug discoveryDrug Discov Today200510211435144216243263
   PubMed Web of Science ®Google Scholar
• BoadoRJAntisense drug delivery through the blood–brain barrierAdv Drug Deliv Rev19951573107
   Web of Science ®Google Scholar
• ModiGPillayVChoonaraYENdesendoVMDu ToitLCNaidooDNanotechnological applications for the treatment of neurodegenerative disordersProg Neurobiol200988427228519486920
   PubMed Web of Science ®Google Scholar
• KhlebtsovNGDykmanLAOptical properties and biomedical applications of plasmonic nanoparticlesJ Quantit Spectrosc Radiat Trans200912135
   Google Scholar
• RoneyCKulkarniARAroraVTargeted nanoparticle delivery through blood–brain barrier for Alzheimer’s diseaseJ Control Release20051082–319321416246446
   PubMed Web of Science ®Google Scholar
• WeissNMillerFCazaubonSCouraudPOThe blood–brain barrier in brain homeostasis and neurological diseasesBiochim Biophys Acta20091788484285719061857
   PubMed Web of Science ®Google Scholar
• BaratchiSKanwarRKKhoshmaneshKPromises of nanotechnology for drug delivery to brain in neurodegenerative diseasesCurr Nanosci20085111
   Web of Science ®Google Scholar
• BlasiPGiovagnoliSSchoubbenARicciMRossiCSolid lipid nanoparticles for targeted brain drug deliveryAdv Drug Deliv Rev200759645447717570559
   PubMed Web of Science ®Google Scholar
• TannerCMEpidemiology of Parkinson’s diseaseNeurol Clin199210923173291584176
   PubMed Web of Science ®Google Scholar
• FinchCEDayJRMolecular biology of aging in the nervous system: a synopsis of the levels of mechanismsCalneDBNeurodegenerative DiseasesPhiladelphia, PASaunders1994
   Google Scholar
• GibbWRLeesAJThe significance of the Lewy body in the diagnosis of idiopathic Parkinson’s diseaseNeuropathol Appl Neurobiol198915127442542825
   PubMed Web of Science ®Google Scholar
• AndertonBHAgeing of the brainMech Ageing Dev2002123781181711869738
   PubMed Web of Science ®Google Scholar
• KurtlandLTAmyotrophic lateral sclerosis and Parkinson’s disease complex on Guam linked to an environmental neurotoxinTrends Neurosci198811251542465598
   PubMed Web of Science ®Google Scholar
• PrzedborskiSVilaMMPTP: a review of its mechanisms of neurotoxicityClin Neurosci Res200116407418
   Web of Science ®Google Scholar
• ReljaMPathophysiology and classification of neurodegenerative diseases Available from: http://ifcc.org.instant.cohaesio.net/ifccfiles/docs/150309200415.pdfAccessed September 3, 2011
   Google Scholar
• WaldmeierPCProspects for antiapoptotic drug therapy of neurodegenerative diseasesProg Neuropsychopharmacol Biol Psychiatry200327230332112657369
   PubMed Web of Science ®Google Scholar
• KanwarJRKanwarRKBurrowHBaratchiSRecent advances on the roles of NO in cancer and chronic inflammatory disordersCurr Med Chem200916192373239419601787
   PubMed Web of Science ®Google Scholar
• ClarkePGHDevelopmental cell death: morphological diversity and multiple mechanismsAnat Embryol199018131952132186664
   PubMedGoogle Scholar
• CuiZLockmanPRAtwoodCSNovel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s disease and other CNS diseasesEur J Pharm Biopharm200559226327215661498
   PubMed Web of Science ®Google Scholar
• NowacekAKosloskiLMGendelmanHENeurodegenerative disorders and nanoformulated drug developmentNanomedicine (Lond)20094554155519572820
   PubMed Web of Science ®Google Scholar
• ScheunerDEckmanCJensenMSecreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s diseaseNat Med1996288648708705854
   PubMed Web of Science ®Google Scholar
• SwartzRHBlackSESt George-HyslopPApolipoprotein E and Alzheimer’s disease: A genetic, molecular and neuroimaging reviewCan J Neurol Sci1999262778810352866
   PubMed Web of Science ®Google Scholar
• WalshDMKlyubinIFadeevaJVNaturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivoNature2002416688053553911932745
   PubMed Web of Science ®Google Scholar
• LambertMPBarlowAKChromyBADiffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxinsProc Natl Acad Sci U S A19989511644864539600986
   PubMed Web of Science ®Google Scholar
• KarranEMerckenMStrooperBDThe amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeuticsNat Rev Drug Discov201110969871221852788
   PubMed Web of Science ®Google Scholar
• ImbimboBPLombardJPomaraNPathophysiology of Alzheimer’s diseaseNeuroimaging Clin N Am200515472775316443487
   PubMed Web of Science ®Google Scholar
• LleóAGreenbergSMGrowdonJHCurrent pharmacotherapy for Alzheimer’s diseaseAnnu Rev Med20065751353316409164
   PubMed Web of Science ®Google Scholar
• Rondi-ReigLLibbeyMEichenbaumHTonegawaSCA1-specific N-methyl-D-aspartate receptor knockout mice are deficient in solving a nonspatial transverse patterning taskProc Natl Acad Sci U S A20019863543354811248114
   PubMed Web of Science ®Google Scholar
• MillerERPastor-BarriusoRDalalDRiemersmaRAAppelLJGuallarEMeta-analysis: high-dosage vitamin E supplementation may increase all-cause mortalityAnn Intern Med20041421374615537682
   PubMed Web of Science ®Google Scholar
• LuoYSmithJVParamasivamVBurdickACurryKJBufordJPInhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761Proc Natl Acad Sci U S A20029919121971220212213959
   PubMed Web of Science ®Google Scholar
• EtminanMGillSSamiiAEffect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and metaanalysis of observational studiesBMJ2003327740712812869452
   PubMed Web of Science ®Google Scholar
• SchenkDBarbourRDunnWImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouseNature1999400674017317710408445
   PubMed Web of Science ®Google Scholar
• FleisherASRamanRSiemersERPhase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer diseaseArch Neurol20086581031103818695053
   PubMedGoogle Scholar
• BardFCannonCBarbourRPeripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer diseaseNat Med20006891691910932230
   PubMed Web of Science ®Google Scholar
• DeMattosRBBalesKRCumminsDJPeripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s diseaseProc Natl Acad Sci U S A200198158850885511438712
   PubMed Web of Science ®Google Scholar
• FillitHHessGHillJBonnerPTosoCIV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disordersNeurology200973318018519620605
   PubMed Web of Science ®Google Scholar
• OddoSBillingsLKessiakJPCribbsDHLaFerlaFMImmunotherapy leads to early, but not late, hyperphosphorylated tau aggregates via the proteasomeNeuron20044332133215294141
   PubMed Web of Science ®Google Scholar
• BachurinSBukatinaELermontovaNAntihistamine agent dimebon as a novel neuroprotector and cognition enhancerAnn N Y Acad Sci200193942543511462798
   PubMed Web of Science ®Google Scholar
• NagaharaAHMerrillDACoppolaGNeuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s diseaseNat Med200915333133719198615
   PubMed Web of Science ®Google Scholar
• CramerPECirritoJRWessonDWApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse modelsScience201233560751503150622323736
   PubMed Web of Science ®Google Scholar
• MichaelJZRobertEBPathophysiology of Parkinson’s disease. NeuropsychopharmacologyCoyleJTCharneyDDavisKLThe Fifth Generation of Progress. An Official Publication of the American College of NeuropsychopharmacologyPhilidelphia, PALippincott Williams and Wilkins1996
   Google Scholar
• GibbWRScottTLeesAJNeuronal inclusions of Parkinson’s diseaseMov Disord1991612111848677
   PubMed Web of Science ®Google Scholar
• PolymeropoulosMHLavedanCLeroyEIdeSEDehejiaAMutation in the α-synuclein gene identified in families with Parkinson’s diseaseScience19972765321204520479197268
   PubMed Web of Science ®Google Scholar
• Van DuijnCMDekkerMCBonifatiVGaljaardRJHouwing-DuistermaatJJPark7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36Am J Hum Genet200169362963411462174
   PubMedGoogle Scholar
• ValenteEMAbou-SleimanPMCaputoVMuqitMMHarveyKHereditary early-onset Parkinson’s disease caused by mutations in PINK1Science200430456741158116015087508
   PubMed Web of Science ®Google Scholar
• HanHWeinrebPHLansburyPTJThe core Alzheimer’s peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?Chem Biol1995231631699383418
   PubMedGoogle Scholar
• KholodilovNGNeystatMOoTFIncreased expression of rat synuclein1 in the substantia nigra pars compacta identified by differential display in a model of developmental target injuryJ Neurochem19997362586259910582622
   PubMed Web of Science ®Google Scholar
• McnaughtKSBelizaireRIsacsonOJennerPOlanowCWAltered proteasomal function in sporadic Parkinson’s diseaseExp Neurol20031791384612504866
   PubMed Web of Science ®Google Scholar
• FahnSCohenGThe oxidant stress hypothesis in Parkinson’s disease: evidence supporting itAnn Neurol19923268048121471873
   PubMed Web of Science ®Google Scholar
• CoskunPWyrembakJSchrinerSA mitochondrial etiology of Alzheimer and Parkinson diseaseBiochim Biophys Acta20121820555356421871538
   PubMed Web of Science ®Google Scholar
• KarlsborgMKorboLRegeurLGladADuodopa pump treatment in patients with advanced Parkinson’s diseaseDan Med Bull2010576A415520515603
   PubMed Web of Science ®Google Scholar
• PagonabarragaJKulisevskyJRasagiline: effectiveness and protection in Parkinson’s diseaseRev Neurol201051953554120979033
   PubMed Web of Science ®Google Scholar
• FreedCRGreenePEBreezeRETransplantation of embryonic dopamine neurons for severe Parkinson’s diseaseN Engl J Med20013441071071911236774
   PubMed Web of Science ®Google Scholar
• ShultsCWHaasRHBealMFA possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s diseaseBiofactors199992–426727210416040
   PubMed Web of Science ®Google Scholar
• HunterCJankovicJDouble-blind, placebo-controlled study to assess safety and efficacy of riluzole as a neuroprotective drug in patients with early untreated Parkinson’s diseaseNeurology199952214221
   Web of Science ®Google Scholar
• KordowerJHPalfiSChenEYClinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s diseaseAnn Neurol199946341943410482276
   PubMed Web of Science ®Google Scholar
• OhiraTShaharEChamblessLERosamondWDMosleyTHJrFolsomARRisk factors for ischemic stroke subtypes: the atherosclerosis risk in communities studyStroke200637102493249816931783
   PubMed Web of Science ®Google Scholar
• TurnerRVinkRInhibition of neurogenic inflammation as a novel treatment for ischemic strokeTimely Top Med Cardiovasc Dis200711E2418297137
   PubMedGoogle Scholar
• KaraszewskiBWardlawJMMarshallIBrain temperature elevation and anaerobic metabolism in human acute ischaemic strokeBrain200932Pt 495596419346327
   PubMed Web of Science ®Google Scholar
• NakanishiNTuSShinYNeuroprotection by the NR3 A subunit of the NMDA receptorJ Neurosci200929165260526519386922
   PubMed Web of Science ®Google Scholar
• JozaNSusinSADaugasEEssential role of the mitochondrial apoptosis-inducing factor in programmed cell deathNature2001410682854955411279485
   PubMed Web of Science ®Google Scholar
• EkshyyanOAwTYApoptosis in neurodegenerative disordersCurr Neurovasc Res20041435537116181084
   PubMed Web of Science ®Google Scholar
• AugustoDEAlvarezLMCostaFTUpdate in spontaneous cerebral hemorrhageMed Intensiva20083228229518601836
   PubMed Web of Science ®Google Scholar
• AdibhatlaRMHatcherJFTissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategiesCNS Neurol Disord Drug Targets20087324325318673209
   PubMed Web of Science ®Google Scholar
• WeyrichASSkalabrinEJKraissLWTargeting the inflammatory response in secondary stroke prevention: a role for combining aspirin and extended-release dipyridamoleAm J Ther200916216417019300042
   PubMed Web of Science ®Google Scholar
• CrouseJRByingtonRPFurbergCDHMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials dataAtherosclerosis1998138111249678767
   PubMed Web of Science ®Google Scholar
• TamSHSassoliPMJordanRENakadaMTAbciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and avb3 integrinsCirculation19989811108510919736595
   PubMed Web of Science ®Google Scholar
• MolinaCASaverJLExtending reperfusion therapy for acute ischemic stroke. Emerging pharmacological, mechanical and imaging strategiesStroke200536102311232016179577
   PubMed Web of Science ®Google Scholar
• LibbyPCurrent concepts of the pathogenesis of the acute coronary syndromesCirculation2001104336537211457759
   PubMed Web of Science ®Google Scholar
• AbeKNeuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapyRinsho Shinkeigaku20084811896898 Japanese19198109
   PubMedGoogle Scholar
• AdibhatlaRMHatcherJFCiticoline mechanisms and clinical efficacy in cerebral ischemiaJ Neurosci Res200270213313912271462
   PubMed Web of Science ®Google Scholar
• ShuaibAYangYLiQEvaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinaseExp Neurol2000161273373910686092
   PubMed Web of Science ®Google Scholar
• AngelIStreinSSchatzGThe lipophilic transition modulator DP-b99 attenuates matrix metalloproteinase activity in a rat MCAO ischaemic model. (Abstract)Soc Neurosci20041003
   Google Scholar
• RosenbergGAngelIKozakAClinical pharmacology of DP-b99 in healthy volunteers: first administration to humansBr J Clin Pharmacol200560171615963088
   PubMed Web of Science ®Google Scholar
• KimHJRoweMRenMHongJSChenPSChuangDMHistone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of actionJ Pharmacol Exp Ther2007321389290117371805
   PubMed Web of Science ®Google Scholar
• Drugs.com [homepage on the Internet]ReNeuron gives uptake on stroke clinical trial. [press release] Available from: http://www.drugs.com/clinical_trials/reneuron-gives-update-stroke-clinical-trial-11261.htmlAccessed September 6, 2011
   Google Scholar
• MoalemGMonsonegoAShaniYCohenIRSchwartzMDifferential T cell response in central and peripheral nerve injury: connection with immune privilegeFASEB J199913101207121710385611
   PubMed Web of Science ®Google Scholar
• StreitWJKincaid-ColtonCAThe brain’s immune systemSci Am1995273554618966536
   PubMed Web of Science ®Google Scholar
• SrogaJMJonesTBKigerlKAMcGaughyVMPopovichPGRats and mice exhibit distinct inflammatory reactions after spinal cord injuryJ Comp Neurol2003462222324012794745
   PubMed Web of Science ®Google Scholar
• StreitWJSemple-RowlandSLHurleySDMillerRCPopovichPGStokesBTCytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosisExp Neurol1998152174879682014
   PubMed Web of Science ®Google Scholar
• LucchinettiCBruckWParisiJScheithauerBRodriguezMLassmannHHeterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelinationAnn Neurol200047670771710852536
   PubMed Web of Science ®Google Scholar
• CharoIFRansohoffRMThe many roles of chemokines and chemokine receptors in inflammationN Engl J Med2006354661062116467548
   PubMed Web of Science ®Google Scholar
• HeppnerFLGreterMMarinoDExperimental autoimmune encephalomyelitis repressed by microglial paralysisNat Med200511214615215665833
   PubMed Web of Science ®Google Scholar
• OntanedaDHylandMCohenJAMultiple sclerosis: new insights in pathogenesis and novel therapeuticsAnnu Rev Med18201163389404
   Google Scholar
• CepokSRoscheGrummelVShort-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosisBrain2005128Pt 71667167615800022
   PubMed Web of Science ®Google Scholar
• SteinmanLA few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantryProc Natl Acad Sci U S A2002936225322568637858
   PubMed Web of Science ®Google Scholar
• Multiple sclerosis Available from: http://www.mayoclinic.org/multiple-sclerosisAccessed September 5, 2011
   Google Scholar
• AxelssonMMalmeströmCNilssonSHaghighiSRosengrenLLyckeJGlial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosisJ Neurol2011258588288821197541
   PubMed Web of Science ®Google Scholar
• HenniesCSternbergDBistulfiGLPlasma pentosidine: a potential biomarker in the management of multiple sclerosisMult Scler201117215716320965962
   PubMed Web of Science ®Google Scholar
• ClericoMContessaGDurelliLInterferon-beta1a for the treatment of multiple sclerosisExpert Opin Biol Ther20077453554217373904
   PubMed Web of Science ®Google Scholar
• ArnonRAharoniRMechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applicationsProc Natl Acad Sci U S A2004101Suppl 2145931459815371592
   PubMed Web of Science ®Google Scholar
• The Merck Manual Home Health HandbookMultiple sclerosis Available from: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/multiple_sclerosis_ms_and_related_disorders/multiple_sclerosis_ms.html?qt=&sc=&alt=Accessed April 26, 2012
   Google Scholar
• ChanAWeilbachFXToykaKVGoldRMitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patientsClin Exp Immunol2005139115215815606626
   PubMed Web of Science ®Google Scholar
• FauciASWolffSMJohnsonJSEffect of cyclophosphamide upon the immune response in Wegener’s granulomatosisN Engl J Med197128527149314965127139
   PubMed Web of Science ®Google Scholar
• MorenoBFernandez-DiezBDi PentaAVillosladaPPreclinical studies of methylthioadenosine for the treatment of multiple sclerosisMult Scler20101691102110820670985
   PubMed Web of Science ®Google Scholar
• MuramatsuTMidkine: a promising molecule for drug development to treat diseases of the central nervous systemCurr Pharm Des201117541042321375488
   PubMed Web of Science ®Google Scholar
• DasguptaSZhouYJanaMBanikNLPahaKSodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple stepsJ Immunol200317073874388212646656
   PubMed Web of Science ®Google Scholar
• FaracoGCavoneLChiarugiAThe therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosisMol Med2011175–644244721373721
   PubMed Web of Science ®Google Scholar
• ZhaoXKanQZhuLZhangGXMatrine suppresses production of IL-23/IL-17 and ameliorates experimental autoimmune encephalomyelitisAm J Chin Med201139593394121905283
   PubMed Web of Science ®Google Scholar
• LutterottiABergerTAdvances in multiple sclerosis therapy: new oral disease-modifying agents, CMLMult Scler20102110
   Google Scholar
• YangJSXuLYXiaoBGHedlundGLinkHLaquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis ratsJ Neuroimmunol20041561–23915465591
   PubMed Web of Science ®Google Scholar
• WarnkeCMeyerHGHartungHPStuveOKieseierBCReview of teriflunomide and its potential in the treatment of multiple sclerosisNeuropsychiatr Dis Treat2009533334019557143
   PubMed Web of Science ®Google Scholar
• EspejoCMontalbaXDalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulationClin Immunol20111421849221742559
   PubMed Web of Science ®Google Scholar
• OsborneRBuzz around Campath proof-of-concept trial in MSNat Biotechnol20092716819131976
   PubMed Web of Science ®Google Scholar
• TaupinPAntibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121Expert Opin Ther Pat201121111111421155688
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEHutchinsonMKapposLMillerDHA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• MarmontAMNew horizons in the treatment of autoimmune diseases: immunoablation and stem cell transplantationAnnu Rev Med20005111513410774456
   PubMed Web of Science ®Google Scholar
• KanwarJRSunXPunjVNanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to healNanomedicine20128439941421889479
   PubMed Web of Science ®Google Scholar
• McKinneyPABrain tumours: incidence, survival, and aetiologyJ Neurol Neurosurg Psychiatry200475ii12ii1715146034
   PubMed Web of Science ®Google Scholar
• BaumannCKZumwaltCBIntracranial neoplasms. An overviewAORN J19895022402422673031
   PubMedGoogle Scholar
• GrahamCACloughesyTFBrain tumor treatment: chemotherapy and other new developmentsSemin Oncol Nurs200420426027215612602
   PubMedGoogle Scholar
• Central Brain Tumor Registry of the United StatesStatistical Report: Primary Brain Tumors in the United States, 1992–1997Chicago, ILCentral Brain Tumor Registry of the United States2000
   Google Scholar
• NelsonDFMartzKLBonnerHNon-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315Int J Radiat Oncol Biol Phys19922319171572835
   PubMed Web of Science ®Google Scholar
• DeAngelisLMSeiferheldWScholdSCFisherBSchultzCJCombination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10J Clin Oncol20022044643464812488408
   PubMed Web of Science ®Google Scholar
• MazzolaCAPollackIFMedulloblastomaCurr Treat Options Neurol20035318919812670407
   PubMedGoogle Scholar
• GalanisEBucknerJSchombergPEffective chemotherapy for advanced CNS embryonal tumors in adultsJ Clin Oncol1997158293929449256138
   PubMed Web of Science ®Google Scholar
• PosnerJBChernikNLIntracranial metastases from systemic cancerAdv Neurol197819579592570349
   PubMedGoogle Scholar
• MischelPSCloughesyTFTargeted molecular therapy of GBMBrain Pathol2003131526112580545
   PubMed Web of Science ®Google Scholar
• Tremonts-LukatsIWGilbertMRAdvances in molecular therapies in patients with brain tumorsCancer Control200310212513712712007
   PubMedGoogle Scholar
• Juillerat-JeanneretLThe targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles?Drug Discov Today20081323–241099110618848640
   PubMed Web of Science ®Google Scholar
• PardridgeWMBlood–brain barrier drug targeting: the future of brain drug developmentMol Interv2003329010514993430
   PubMedGoogle Scholar
• MizunoNNiwaTYotsumotoYSugiyamaYImpact of drug transporter studies on drug discovery and developmentPharmacol Rev200355342546112869659
   PubMed Web of Science ®Google Scholar
• EgletonRDDavisTPDevelopment of neuropeptide drugs that cross the blood–brain barrierNeuro Rx200521445315717056
   PubMedGoogle Scholar
• PardridgeWMMolecular Trojan horses for blood–brain barrier drug deliveryCurr Opin Pharmacol20066549450016839816
   PubMed Web of Science ®Google Scholar
• NiidomeTYamagataMOkamotoYPEG-modified gold nanorods with a stealth character for in vivo applicationsJ Control Release200611434334716876898
   PubMed Web of Science ®Google Scholar
• De JongWHBormPJDrug delivery and nanoparticles: applications and hazardsInt J Nanomedicine20083213314918686775
   PubMed Web of Science ®Google Scholar
• LockmanPRMumperRJKhanMAAllenDDNanoparticle technology for drug delivery across the blood–brain barrierDrug Dev Ind Pharm200228111311858519
   PubMed Web of Science ®Google Scholar
• RapoportSIOhnoKFredericksWRPettigrewKDRegional cerebrovascular permeability to [14C] sucrose after osmotic opening of the blood–brain barrierBrain Res19781503653657678996
   PubMed Web of Science ®Google Scholar
• PhillipsMAGranMLPeppasNATargeted nanodelivery of drugs and diagnosticsNano Today20105214315920543895
   PubMed Web of Science ®Google Scholar
• PardridgeWMReceptor-mediated peptide transport through the blood–brain barrierEndocr Rev1986733143303017689
   PubMed Web of Science ®Google Scholar
• PardridgeWMKangYSBuciakJLYangJHuman insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid trans-cytosis through the blood–brain barrier in vivo in the primatePharm Res19951268078167667183
   PubMed Web of Science ®Google Scholar
• FridenPMAlkermes IncTransferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugatesUnited States Patent US583398811101998
   Google Scholar
• PardridgeWMWuDSakaneTCombined use of carboxyldirected protein pegylation and vector-mediated blood–brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administrationPharm Res19981545765829587954
   PubMed Web of Science ®Google Scholar
• StarrCMZankelTGabathulerRBiomarin Pharmaceutical IncDelivery of therapeutic compounds to the brain and other tissuesCA25252361132005
   Google Scholar
• WuDYangJPardridgeWMDrug targeting of a peptide radio pharmaceutical through the primate blood–brain barrier in vivo with a monoclonal antibody to the human insulin receptorJ Clin Invest19971007180418129312181
   PubMed Web of Science ®Google Scholar
• ForniFVandelliMAConstantinoLUniversita’ Degli Studi Di Modena Reggio Emilia EDrug delivery peptides for crossing blood–brain barrierEuropean Patent application EP200508179098222007
   Google Scholar
• RobertsMJBentleyMDHarrisJMChemistry for peptide and protein PEGylationAdv Drug Deliv Rev200254445947612052709
   PubMed Web of Science ®Google Scholar
• HuKLiJShenYLactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluationsJ Control Release20091341556119038299
   PubMed Web of Science ®Google Scholar
• KreuterJNanoparticulate systems for brain delivery of drugsAdv Drug Deliv Rev2001471658111251246
   PubMed Web of Science ®Google Scholar
• SteinigerSCKreuterJKhalanskyASChemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticlesInt J Cancer2004109575976714999786
   PubMed Web of Science ®Google Scholar
• WangCXHuangLSHouLBAntitumor effects of polysorbate- 80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor modelBrain Res20091261919919401168
   PubMed Web of Science ®Google Scholar
• PetriBBootzAKhalanskyAChemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactantsJ Control Release20071171515817150277
   PubMed Web of Science ®Google Scholar
• GelperinaSMaksimenkoOKhalanskyADrug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parametersEur J Pharm Biopharm201074215716319755158
   PubMed Web of Science ®Google Scholar
• KulkarniSAFengSSEffects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood–brain barrierNanomedicine20116237739421385139
   PubMed Web of Science ®Google Scholar
• PandeyRSharmaAZahoorASharmaSKhullerGKPoly(dl-lactide- co-glycolide) nanoparticles based inhalable sustained drug delivery system for experimental tuberculosisJ Antimicrob Chemother200352698198614613962
   PubMed Web of Science ®Google Scholar
• GanCWFengSSTransferrin-conjugated nanoparticles of poly(lactide)-d-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood–brain barrierBiomaterials201031307748775720673685
   PubMed Web of Science ®Google Scholar
• CarrollRTBhatiaDGeldenhuysWBrain-targeted delivery of Tempol-loaded nanoparticles for neurological disordersJ Drug Target201018966567420158436
   PubMed Web of Science ®Google Scholar
• HuangRKeWHanLLiuYShaoKJiangCLactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivoBrain Res Bull201081660060420026388
   PubMed Web of Science ®Google Scholar
• AgyareEKCurranGLRamakrishnanMYuCCPodusloJFKandimallaKKDevelopment of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer’s disease and cerebral amyloid angiopathyPharm Res200825112674268418712585
   PubMed Web of Science ®Google Scholar
• WangZHWangZYSunCSWangCYJiangTYWangSLTrimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brainBiomaterials201031590891519853292
   PubMed Web of Science ®Google Scholar
• NeelyAPerryCVarisliBUltrasensitive and highly selective detection of Alzheimer’s disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticleACS Nano2009392834284019691350
   PubMed Web of Science ®Google Scholar
• HuangSLiJHanLDual target ing effect of Angiopep- 2-modified, DNA-loaded nanoparticles for glcomaBiomaterials201132386832683821700333
   PubMed Web of Science ®Google Scholar
• HuangRKeWHanLLiJLiuSJiangCTargeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administrationBiomaterials20113292399240621185076
   PubMed Web of Science ®Google Scholar
• HuileGShuaiqiPZhiYA cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 proteinBiomaterials201132338669867521843903
   PubMed Web of Science ®Google Scholar
• TianXHLinXNWeiFEnhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticlesInt J Nanomedicine2011644545221445277
   PubMed Web of Science ®Google Scholar
• GuoJGaoXSuLAptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug deliveryBiomaterials201132318010802021788069
   PubMed Web of Science ®Google Scholar
• FillmoreHLShultzMDHendersonSCConjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumorsNanomedicine (Lond)20116344945821542684
   PubMed Web of Science ®Google Scholar
• LiJFengLFanLTargeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptidesBiomaterials201132214943495021470674
   PubMed Web of Science ®Google Scholar
• ParkJGaoWWhistonRStromTBMetcalfeSFahmyTMModulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine deliveryMol Pharm20118114315220977190
   PubMed Web of Science ®Google Scholar
• Van KasterenSICampbellSJSerresSAnthonyDCSibsonNRDavisBGGlyconanoparticles allow pre-symptomatic in vivo imaging of brain diseaseProc Natl Acad Sci U S A20091061182319106304
   PubMed Web of Science ®Google Scholar
• YurkoYMaximovVAndreozziEThompsonGLVertegelAADesign of biomedical nanodevices for dissolution of blood clotsMater Sci Eng C Mater Biol Appl2009293737741
   Web of Science ®Google Scholar
• MarshJNHuGScottMJA fibrin-specific thrombolytic nanomedicine approach to acute ischemic strokeNanomedicine (Lond)20116460561521506686
   PubMed Web of Science ®Google Scholar
• BaratchiSKanwarRKKanwarJRSurvivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stressPLoS One201161e1586521249229
   PubMed Web of Science ®Google Scholar
• BaratchiSKanwarRKAntonio CheungCHKanwarJRProliferative and protective effects of SurR9-C84A on differentiated neural cellsJ Neuroimmunol20102271–212013220709413
   PubMed Web of Science ®Google Scholar
• WynneAKanwarRKKhannaRKanwarJRRecent advances on the possible neuroprotective activities of Epstein-Barr virus oncogene BARF1 protein in chronic inflammatory disorders of central nervous systemCurr Neuropharmacol20108326827521358976
   PubMed Web of Science ®Google Scholar
• KanwarJRKanwarRKKrissansenGWSimultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitisBrain2004127Pt 61313133115130951
   PubMed Web of Science ®Google Scholar
• KanwarJRKanwarRKWangDKrissansenGWPrevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progressionImmunol Cell Biol200078664164511114975
   PubMed Web of Science ®Google Scholar
• KanwarJRHarrisonJEBWangDb7 integrins contribute to demyelinating disease of the central nervous systemJ Neuroimmunol2000103214615210696909
   PubMed Web of Science ®Google Scholar
• WengelJSynthesis of 3′-C- and 4′-C- branched oligonucleotides and the development of locked nucleic acid (LNA)Acc Chem Res199932301310
   Web of Science ®Google Scholar